Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Pharmaceuticals & Biotechnology | Small Cap
Health Score : 7.52Windlas Biotech demonstrates a mixed financial performance. The company shows strong solvency, growth, coverage, and profitability. It maintains a very low level of debt and robust growth in revenue, operating profit, and earnings per share, alongside excellent interest and dividend coverage. Profitability metrics such as gross profit margin, ROCE, ROE, ROA, and operating and net margins are also very strong. However, there are concerns regarding liquidity and efficiency. The company's liquidity ratios suggest challenges in meeting short-term obligations, while efficiency ratios indicate potential issues with asset utilization, particularly in fixed assets and capital turnover. Financial ratios also present some weaknesses. Overall, Windlas Biotech exhibits solid financial health driven by growth and profitability, but needs to address areas related to liquidity and efficiency to ensure long-term stability and performance.
Health Score : 7.52Windlas Biotech demonstrates a mixed financial performance. The company shows strong solvency, growth, coverage, and profitability. It maintains a very low level of debt and robust growth in revenue, operating profit, and earnings per share, alongside excellent interest and dividend coverage. Profitability metrics such as gross profit margin, ROCE, ROE, ROA, and operating and net margins are also very strong. However, there are concerns regarding liquidity and efficiency. The company's liquidity ratios suggest challenges in meeting short-term obligations, while efficiency ratios indicate potential issues with asset utilization, particularly in fixed assets and capital turnover. Financial ratios also present some weaknesses. Overall, Windlas Biotech exhibits solid financial health driven by growth and profitability, but needs to address areas related to liquidity and efficiency to ensure long-term stability and performance.
Overall Valuation Score
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
Today's Low: 0.00
Today's High: 0.00
P/E RATIO (TTM)
31.32
Industry Median
30.91
Small Cap Median
28.64
P/E RATIO
32.03
P/B RATIO
3.67
Industry Median
3.69
Small Cap Median
3.11
P/S RATIO
2.26
Industry Median
3.74
Small Cap Median
3.02
Others
PEG RATIO
0.00
EV/EBITDA RATIO
16.67
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹1008.35 as on Sep 1, 2026.
Growth Score : 10.00The company exhibits excellent growth across all key metrics. Strong revenue growth, operating profit growth, EPS growth, asset growth, and net income growth reflect robust business expansion and effective management strategies. This indicates a positive trajectory and strong potential for future performance. The company is effectively scaling its operations and profitability.
Revenue Growth RateExcellentOperating Profit Growth RateExcellentEarnings Per Share (EPS) GrowthExcellentAsset Growth RateExcellentNet Income Growth RateExcellent| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 8.88 | 10.09 | 23 | 20.44 | 18.95 |
| Operating Profit Growth Rate | -3.64 | 13.21 | 30 | 20.51 | 11.7 |
| Earnings Per Share (EPS) Growth | 126.5 | 13.34 | 39.4 | 3.54 | 8.78 |
| Asset Growth Rate | 65.88 | 7.74 | 18.34 | 21.41 | 19.34 |
| Net Income Growth Rate | 680 | 10.26 | 34.88 | 5.17 | 8.2 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
No Peer Data Is Available at This Moment.
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Analyzing moving average trends and crossovers. Green/Red badges indicate if the current condition passes or fails.
Comparing stock price performance (normalized) against benchmark indices over time.
Recent daily trading volume represented as a bar chart, alongside historical averages.
Current closing price relative to the 52-week highest and lowest prices.
No Stock Reports Available at This Moment.
Windlas Biotech Ltd. is a leading Indian pharmaceutical CDMO and branded generics manufacturer. It specializes in dry powder injectables, oral solids, and liquid orals, offering comprehensive product development and large-scale manufacturing services. The company caters to chronic therapy areas like cardiovascular, CNS, and diabetes, establishing a strong presence in the domestic and international markets.
P/E Ratio (TTM): Price to Earnings ratio shows how much an investor pays for every rupee of the company's earnings. Windlas Biotech Ltd's P/E ratio (TTM) is 31.32, compared to the industry median of 30.91 and large cap median of 28.64.
P/B Ratio: Price to Book ratio compares a company's market price to its book value per share. Windlas Biotech Ltd's P/B ratio is 3.67, compared to the industry median of 3.69 and large cap median of 3.11.
P/S Ratio: Price to Sales ratio compares a company's market value to its total revenue. Windlas Biotech Ltd's P/S ratio is 2.26, compared to the industry median of 3.74 and large cap median of 3.02.
PEG Ratio: PEG ratio adjusts the P/E ratio for expected earnings growth. Windlas Biotech Ltd's PEG ratio is 0.58.
EV/EBITDA Ratio: This ratio compares a company's enterprise value to its earnings before interest, tax, depreciation, and amortization. Windlas Biotech Ltd's EV/EBITDA ratio is 16.67.
Return on Equity (ROE): ROE measures how much profit a company generates from shareholders' invested capital. Windlas Biotech Ltd's ROE is 11.36%.
Return on Assets (ROA): ROA measures how efficiently a company converts its assets into net profit. Windlas Biotech Ltd's ROA is 11.58%.
Return on Capital Employed (ROCE): ROCE measures how efficiently a company generates profit from all the capital it employs. Windlas Biotech Ltd's ROCE is 16%.
Operating Margin: Operating margin shows what percentage of revenue remains after covering operating expenses. Windlas Biotech Ltd's operating margin is 11.62%.
Net Margin: Net margin shows what percentage of revenue converts into final net profit. Windlas Biotech Ltd's net margin is 7.30%.
Current Ratio: The current ratio measures a company's ability to pay short-term liabilities using short-term assets. Windlas Biotech Ltd's current ratio is 1.14.
Debt to Equity Ratio: This ratio shows the proportion of debt a company uses relative to shareholders' equity. Windlas Biotech Ltd's debt-to-equity ratio is 0.01.
Interest Coverage Ratio: This ratio shows how easily a company can pay interest on its outstanding debt from its operating earnings. Windlas Biotech Ltd's interest coverage ratio is 18.40.
Dividend Per Share (DPS): DPS shows the total dividend paid per share in the latest financial year. Windlas Biotech Ltd's DPS is ₹6.30.
Earnings Per Share (EPS): EPS shows how much profit is allocated to each outstanding share. Windlas Biotech Ltd's EPS is 8.78.
(Source line: "Ratios as of 25 Sept 2026, based on last traded price of ₹1008.35. Data sourced from BSE/NSE Exchange Filings & Public Terminal Data.")
Founded: 2001
Headquarters: Dehradun, Uttarakhand
Core Offerings: Contract Development and Manufacturing Organization (CDMO) Services, Branded Generics Manufacturing, Pharmaceutical Development Services, Product Lifecycle Management
Stock Listing: NSE (WINDLAS), BSE (543329)
Promoter: Handa Family / Windlas Biotech Limited Promoter Group
Windlas Biotech was incorporated in 2001 as Windlas Biotech Private Limited. Commercial production commenced at its Dehradun Unit I in 2004. The company expanded its manufacturing capabilities with the addition of Unit II and Unit III facilities in 2008, enhancing capacity for liquid injectables, pre-filled syringes, oral solids, and dry powder injectables. Throughout the 2010s, it focused on strengthening its CDMO partnerships and expanding its branded generics portfolio. In 2021, Windlas Biotech successfully launched its Initial Public Offering (IPO), listing on both NSE and BSE. Today, it continues to grow its presence in both CDMO and branded product segments, focusing on chronic and acute therapeutic areas.
| Segment Name | Revenue % | EBITDA |
|---|---|---|
| CDMO Services & Pharmaceutical Development Services (PDS) | 72% | Operating Profit |
| Branded Products (including Branded Generics & Trade Generics) | 28% | Operating Profit |
CDMO Services & Pharmaceutical Development Services (PDS): Provides end-to-end contract development and manufacturing for pharmaceutical companies, including product conceptualization, formulation development, clinical trial supply, and commercial manufacturing. Focuses on dry powder injectables, oral solids, and liquid orals, serving both domestic and international clients.
Branded Products: Encompasses the manufacturing and marketing of Windlas Biotech's own portfolio of branded generic medicines, primarily for the Indian domestic market. This segment also includes trade generics distributed through various channels, targeting chronic and acute therapy segments.
Mr. Ashok Kumar Windlas: Chairman and Managing Director. A visionary leader with over three decades of extensive experience in the pharmaceutical industry, he founded Windlas Biotech and has been instrumental in shaping its strategic direction and growth.
No major subsidiaries reported.
IPO (August 2021) for listing on NSE and BSE. No major recent corporate actions on record.
The Windlas Biotech Ltd share price today is ₹1008.35 on NSE (WINDLAS), as of 26 Sept 2026.
As of 25 Sept 2026, Windlas Biotech Ltd share price is ₹1008.35, with previous close ₹1008.35. Today's range is ₹1008.35 to ₹1008.35. The 52-week range is ₹697.40 to ₹1181.90.
As of today, Windlas Biotech Ltd's market cap is ₹2,046.95 crore (Small Cap).
Windlas Biotech Ltd's current P/E ratio is 31.32, compared to the PHARMACEUTICALS & BIOTECHNOLOGY sector average of 38.
Windlas Biotech Ltd's current P/B ratio is 3.67.
Windlas Biotech Ltd's current dividend yield is 0.62%. Last dividend of ₹3.00 per share was declared on 23-May-2024.
Windlas Biotech Ltd's EPS (TTM) is ₹8.78.
Windlas Biotech Ltd. is a leading Indian pharmaceutical CDMO and branded generics manufacturer. It specializes in dry powder injectables, oral solids, and liquid orals, offering comprehensive product development and large-scale manufacturing services. The company caters to chronic therapy areas like cardiovascular, CNS, and diabetes, establishing a strong presence in the domestic and international markets.
Windlas Biotech Ltd is promoted by Handa Family / Windlas Biotech Limited Promoter Group, holding 61.9% as of 25 Sept 2026.
Windlas Biotech Ltd is listed on NSE (WINDLAS) and BSE (543329). Its next quarterly results are expected on August 2024.
Capital Expenditures (CapEx)
